Cidara Therapeutics Q3 Financial Results SAN DIEGO, November 06, 2025, Cidara Therapeutics, Inc. (CDTX) reported financial results for the third quarter ended September 30, 2025, and provided recent business updates. From Cidara Therapeutics Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, said, “With our Phase 3 ANCHOR study now over 50 percent enrolled, we expect to achieve target enrollment . . . This …
Cidara Therapeutics Cidara Therapeutics (CDTX) is using its proprietary Cloud break® platform to develop novel drug-Fc conjugate (DFC) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In . . . This content …
Cidara Therapeutics Cidara Therapeutics uses its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track …
Outperforming Biotechs On August 27, 2019 we posted “The Medicines Company Has Agreeable News” under Today’s Highlights. The Medicines Company We described The Medicines Company (MDCO) as a firm focused on cardiovascular diseases with a goal of halting the progression of atherosclerosis and lowering the cardiovascular risk caused by high levels of LDL Cholesterol (LDL-C). The Medicines Company’s good news emanated from the results of …
Cidara Therapeutics (CDTX), a biotechnology company developing novel anti-infective products, including immunotherapies, announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), awarded it and Rutgers University a five-year, $5.5 million partnership grant. The grant aimed at funding the continued research and development of Cidara’s innovative Cloudbreak™antibody-drug conjugate (ADC) platform to identify novel immunotherapy agents for the treatment and prevention of serious and life-threatening multi-drug resistant (MDR) Gram …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
